MedPath

A non-interventional study to investigate the proportion, characteristics and treatment reality of adult patients with severe and uncontrolled severe asthma using a claims database

Not Applicable
Conditions
Asthma
Registration Number
JPRN-UMIN000027695
Lead Sponsor
Astrazeneca K.K
Brief Summary

The primary analysis set consisted of 10,579 'athma patients under treatment'. 'Athma patients under treatment' included 823 'severe asthma patients'(7.8%). The number (%) of 'uncontrolled severe asthma patients' was 267 patients (2.5%), and that of 'non-severe patients' was 9,756 (92.2%). Compared to 'non-severe patients', 'uncontrolled severe asthma patients' had a higher frequency in asthma exacerbation and more expensive direct medical expenditure. Also, compared to 'non-severe patients', 'uncontrolled severe asthma patients' had a higher amount of use of systemic steroids.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
20000
Inclusion Criteria

Not provided

Exclusion Criteria

-Patients who didin't have the "claims with for an asthma and record of ICS or ICS/LABA prescription for that visit" within 6 months prior to Index date -Patients who didin't have the "claims with for an asthma and record of ICS or ICS/LABA prescription for that visit" during the period of more than 6 months and within 12 months prior to Index date

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath